Ubs Group Ag Cellectar Biosciences, Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$3.5 - $6.9 $80,997 - $159,679	23,142 Added 140.25%	39,642 $16,000
Q1 2022 May 16, 2022	SELL	$4.6 - $7.8 $163,106 - $276,572	-35,458 Reduced 68.24%	16,500 $11,000
Q4 2021 Feb 14, 2022	BUY	$6.1 - $10.2 $246,793 - $412,671	40,458 Added 351.81%	51,958 $34,000
Q2 2021 Aug 13, 2021	BUY	$11.8 - $18.2 $112,100 - $172,900	9,500 Added 475.0%	11,500 $14,000
Q1 2021 May 12, 2021	BUY	$15.2 - $25.0 $8,132 - $13,375	535 Added 36.52%	2,000 $3,000
Q4 2020 Feb 11, 2021	BUY	$11.2 - $27.7 $16,408 - $40,580	1,465 New	1,465 $3,000
Q3 2020 Nov 12, 2020	SELL	$10.6 - $16.6 $12,137 - $19,007	-1,145 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$10.3 - $17.3 $5,582 - $9,376	542 Added 89.88%	1,145 $1,000
Q1 2020 May 01, 2020	BUY	$11.0 - $31.7 $6,633 - $19,115	603 New	603 $1,000
Q1 2019 May 14, 2019	SELL	$15.8 - $28.5 $89,996 - $162,336	-5,696 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$12.9 - $36.9 $40,699 - $116,419	3,155 Added 124.16%	5,696 $9,000
Q3 2018 Nov 14, 2018	BUY	$21.9 - $79.0 $55,647 - $200,739	2,541 New	2,541 $8,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.